

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/508,251	04/10/2000	NAOSHI FUKUSHIMA	065678/0101	9585
75	590 01/10/2003			
STEPHEN B MAEBIUS			EXAMINER	
FOLEY & LARDNER 3000 K STREET NW SUITE 500 WASHINGTON HARBOUR WASHINGTON, DC 20007-5109			HELMS, LARRY RONALD	
			ART UNIT	PAPER NUMBER
			1642	I/A
			DATE MAILED: 01/10/2003	, 19

Please find below and/or attached an Office communication concerning this application or proceeding.

3	Application No.	Applicant(s)			
Advisory Action	09/508,251	FUKUSHIMA ET AL.			
naviosity naudin	Examiner	Art Unit			
	Larry R. Helms	1642			
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence address			
THE REPLY FILED 11 December 2002 FAILS TO PLACE Therefore, further action by the applicant is required to avinal rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this applica a timely filed amendment whicl	ation. A proper reply to a n places the application in			
PERIOD FOR RE	PLY [check either a) or b)]				
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The ee have been filed is the date for purposes of determining the period dee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of 2) as set forth in (b) above, if checked. Any reply received by the Officimely filed, may reduce any earned patent term adjustment. See 37 C	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF The date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply the later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension on the fee. The appropriate extension originally set in the final Office action; or			
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF					
2. $igtimes$ The proposed amendment(s) will not be entered be	ecause:				
(a) X they raise new issues that would require further	er consideration and/or search (	see NOTE below);			
(b) they raise the issue of new matter (see Note b	elow);	. *			
(c)  they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the			
(d)  they present additional claims without cancell	ng a corresponding number of fi	nally rejected claims.			
NOTE: See Continuation Sheet.					
3. ☐ Applicant's reply has overcome the following rejecti	on(s):	* .			
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment			
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: see		dered but does NOT place the			
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly			
	For purposes of Appeal, the proposed amendment(s) a) will not be entered or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.				
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed: none.	Claim(s) allowed: <u>none</u> .				
Claim(s) objected to: <u>19</u> .					
Claim(s) rejected: <u>13-18, 20-21</u> .					
Claim(s) withdrawn from consideration:					
8. The proposed drawing correction filed on is	a)□ approved or b)□ disapp	roved by the Examiner.			
9. Note the attached Information Disclosure Statemer	nt(s)( PTO-1449) Paper No(s)				
0. Other:					
	M				

Continuation Sheet (PTO-303)





Application No. 09/508,251

Continuation of 2. NOTE: newly amended claims 20-21 and newly proposed added claims 24-25 are directed to a new invention of a method for treatine leukemia as oposed to the claims under examination which are directed to the product of a monoclonal antibody. As such the new claims require a completely different search and different donsidurations..